These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 19117686)

  • 1. Microtubule dynamics as a target in oncology.
    Risinger AL; Giles FJ; Mooberry SL
    Cancer Treat Rev; 2009 May; 35(3):255-61. PubMed ID: 19117686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microtubule-binding natural products for cancer therapy.
    Yue QX; Liu X; Guo DA
    Planta Med; 2010 Aug; 76(11):1037-43. PubMed ID: 20577942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epothilones and new analogues of the microtubule modulators in taxane-resistant disease.
    Harrison M; Swanton C
    Expert Opin Investig Drugs; 2008 Apr; 17(4):523-46. PubMed ID: 18363517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
    Perez EA
    Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Microtubule Drugs.
    Florian S; Mitchison TJ
    Methods Mol Biol; 2016; 1413():403-21. PubMed ID: 27193863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
    Fojo T; Menefee M
    Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tubulin interacting agents: novel taxanes and epothilones.
    Agrawal NR; Ganapathi R; Mekhail T
    Curr Oncol Rep; 2003 Mar; 5(2):89-98. PubMed ID: 12583825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ixabepilone: a new microtubule-targeting agent for breast cancer.
    Higa GM; Abraham J
    Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanosolvated microtubule-modulating chemotherapeutics: a case-to-case study.
    Jain V; Jain B; Tiwari P; Saini J; Jain UK; Pandey RS; Kumar M; Katare OP; Chandra R; Madan J
    Anticancer Drugs; 2013 Apr; 24(4):327-36. PubMed ID: 23411683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential mechanisms of resistance to microtubule inhibitors.
    Kavallaris M; Annereau JP; Barret JM
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microtubule active agents: beyond the taxane frontier.
    Morris PG; Fornier MN
    Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function.
    Escuin D; Kline ER; Giannakakou P
    Cancer Res; 2005 Oct; 65(19):9021-8. PubMed ID: 16204076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells.
    Wilmes A; O'Sullivan D; Chan A; Chandrahasen C; Paterson I; Northcote PT; La Flamme AC; Miller JH
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):117-26. PubMed ID: 20848285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-taxoid site microtubule-stabilizing drugs work independently of tau overexpression in mouse N2a neuroblastoma cells.
    Das V; Miller JH
    Brain Res; 2012 Dec; 1489():121-32. PubMed ID: 23085090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanism of action of microtubule-stabilizing anticancer agents.
    Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO
    Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.